Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes

References

• Laing S. P., Swerdlow A. J., Slater S. D., Burden A. C., Morris A., Waugh N. R., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin‐treated diabetes. Diabetologia 2003; 46: 760–5
   PubMed Web of Science ®Google Scholar
• Tuomilehto J., Borch‐Johnsen K., Molarius A., Forsén T., Rastenyte D., Sarti C., et al. Incidence of cardiovascular disease in Type 1 (insulin‐dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784–90
   PubMed Web of Science ®Google Scholar
• Stamler J., Vaccaro O., Neaton J. D., Wentworth D. Diabetes, other risk factors, and 12‐yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434–44
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Roitman‐Johnson M. J., Stampfer J. A., Allen J. Plasma concentration of soluble intercellular adhesion molecule‐1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92
   PubMed Web of Science ®Google Scholar
• Nygard O., Nordrehaug J. E., Refsum H., Ueland P. M., Farstad M., Vollset S. E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–6
   PubMed Web of Science ®Google Scholar
• Schulze F., Lenzen H., Hanefeld C., Bartling A., Osterziel K., Goudeva L., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.e1–e8
   Web of Science ®Google Scholar
• Cesari M., Pessina A. C., Zanchetta M., De Toni R., Avogaro A., Pedon L., et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high‐risk nondiabetic patients. J Intern Med 2006; 260: 474–83
   PubMed Web of Science ®Google Scholar
• Creager M. A., Lüscher T. F., Beckman J. A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527–32
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6: 7–14
   PubMed Web of Science ®Google Scholar
• Coppey L. J., Gellett J. S., Davidson E. P., Dunlap J. A., Lund D. D., Yorek M. A. Effect of antioxidant treatment of streptozotocin‐induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927–37
   PubMed Web of Science ®Google Scholar
• Seckin D., Ilhan N., Ilhan N., Ertugrul S. Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diabetes Res Clin Pract 2006; 73: 191–7
   PubMedGoogle Scholar
• Segarra G., Medina P., Vila J. M., Chuan P., Domenech C., Torondel B., et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14: 1142–18
   PubMedGoogle Scholar
• The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke – a meta‐analysis. J Am Med Assoc 2002; 288: 2015–22
   PubMed Web of Science ®Google Scholar
• Schwartz G. J., Haycock G. B., Edelmann C. M Jr., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259–63
   PubMed Web of Science ®Google Scholar
• Järvisalo M. J., Raitakari M., Toikka J. O., Putto‐Laurila A., Rontu R., Laine S., et al. Endothelial dysfunction and increased arterial intima‐media thickness in children with type 1 diabetes. Circualtion 2004; 109: 1750–5
   PubMed Web of Science ®Google Scholar
• Ridker P. M. Clinical application of C‐reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363–9
   PubMed Web of Science ®Google Scholar
• Pearson T. A., Mensah G. A., Alexander R. W., Anderson J. L., Cannon R. O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511
   PubMed Web of Science ®Google Scholar
• Päiva H., Laakso J., Ruokanen I., Turjanmaa V., Kööbi T., Majahalme S., et al. Plasma asymmetric dimethylarginine (ADMA), nitrate and the indices of low‐density lipoprotein oxidation. Clin Chim Acta 2006; 371: 97–101
   PubMedGoogle Scholar
• Tarnow L., Hovind P., Teerlink T., Stehouwer C. D. A., Parving H‐H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765–9
   PubMed Web of Science ®Google Scholar
• Hofmann M. A., Kohl B., Zumbach M. S., Borcea V., Bierhaus A., Henkels M., et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998; 21: 841–8
   PubMed Web of Science ®Google Scholar
• Buysschaert M., Dramais A. S., Wallemacq P. E., Hermans M. P. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy and insulin resistance. Diabetes Care 2000; 23: 1816–22
   PubMed Web of Science ®Google Scholar
• Cotellessa M., Minniti G., Cerone R., Prigione F., Calevo M. G., Lorini R. Low total plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 2001; 24: 969–71
   PubMedGoogle Scholar
• Meloni G. F., Tonolo G. C., Zuppi C., Zappacosta B., Musumeci S. Hyper‐homocysteinemia is not a main feature of juvenile uncomplicated type 1 diabetes. J Atheroscler Thromb 2005; 12: 14–19
   PubMed Web of Science ®Google Scholar
• Wiltshire E., Thomas D. W., Baghurst P., Couper J. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr 2001; 138: 888–93
   PubMedGoogle Scholar
• Vilaseca M. A., Moyano D., Ferrer I., Artuch R. Total homocysteine in pediatric patients. Clin Chem 1997; 43: 690–2
   PubMed Web of Science ®Google Scholar
• Wollesen F., Brattström L., Refsum H., Ueland P. M., Berglund L., Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028–35
   PubMed Web of Science ®Google Scholar
• Abu‐Lebdeh H. S., Barazzoni R., Meek S. E., Bigelow M. L., Persson X. M., Nair K. S. Effects of insulin deprivation and treatment on homocysteine metabolism in people with type 1 diabetes. J Clin Endocrinol Metab 2006; 91: 3344–8
   PubMedGoogle Scholar
• Celi F., Bini V., Papi F., Santilli E., Castellani M. S., Ferretti A., et al. Circulating adipocytokines in non‐diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabetes Med 2006; 23: 660–5
   PubMedGoogle Scholar
• Galler A., Gelbrich G., Kratzsch J., Noack N., Kapellen T., Kiess W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol 2007; 157: 481–9
   PubMed Web of Science ®Google Scholar
• Lindsay R. S., Funahashi T., Hanson R. L., Matsuzawa Y., Tanaka S., Tataranni P. A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57–8
   PubMed Web of Science ®Google Scholar
• Okamoto Y., Kihara S., Funahashi T., Matsuzawa Y., Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267–78
   PubMed Web of Science ®Google Scholar
• Heliövaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins. Exp Clin Endocrinol Diabetes 2006; 114: 295–300
   PubMedGoogle Scholar
• Imagawa A., Funahashi T., Nakamura T., Moriwaki M., Tanaka S., Nishizawa H., et al. Elevated serum concentration of adipose‐derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002; 25: 1665–6
   PubMed Web of Science ®Google Scholar
• Frystyk J., Tarnow L., Hansen T., Parving H. H., Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48: 1911–18
   PubMed Web of Science ®Google Scholar
• Zoccali C., Mallamaci F., Tripepi G., Benedetto F. A., Tripepi G., Malatino L., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end‐stage renal disease. J Am Soc Nephrol 2002; 13: 134–41
   PubMed Web of Science ®Google Scholar
• Looker H. C., Krakoff J., Funahashi T., Matsuzawa Y., Tanaka S., Nelson R. G., et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010–17
   PubMedGoogle Scholar
• Schalkwijk C. G., Chaturvedi N., Schram M. T., Fuller J. H., Stehouwer C. D., the EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006; 91: 129–35
   PubMedGoogle Scholar
• Malyszko J., Malyszko J. S., Brzosko S., Wolczynski S., Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004; 89: 4620–7
   PubMedGoogle Scholar
• Delaigle A. M., Jonas J. C., Bauche I. B., Cornu O., Brichard S. M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004; 145: 5589–97
   PubMed Web of Science ®Google Scholar
• Wannamethee S. G., Whincup P. H., Lennon L., Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510–17
   PubMedGoogle Scholar
• Dekker J. M., Funahashi T., Nijpels G., Pilz S., Stehouwer C. D., Snijder M. B., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489–96
   PubMedGoogle Scholar
• Mortensen H. B., Hougaard P. Comparison of metabolic control in a cross‐sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidøre Study Group on Childhood Diabetes. Diabetes Care 1997; 20: 714–20
   PubMedGoogle Scholar
• Danne T., Mortensen H. B., Hougaard P., Lynggaard H., Aanstoot H. J., Chiarelli F., et al. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care 2001; 24: 1342–7
   PubMedGoogle Scholar
• Aso Y., Yamamoto R., Wakabayashi S., Uchida T., Takayanagi K., Takebayashi K., et al. Comparison of serum high‐molecular weight (HMW) adiponectin with total adiponectin concentrations in Type 2 diabetic patients with coronary artery disease using a novel enzyme‐linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006; 55: 1954–60
   PubMed Web of Science ®Google Scholar